Opdivo trials show sustained improvements for patients with advanced NSCLC
Opdivo gave patients an overall survival benefit for the landmark two-year time point compared to docetaxel. The data demonstrate that Opdivo could help the overall population, including CheckMate-057 (double) and Checkmate-017 (triple) patients still alive after two years.
“These new data from CheckMate -057 and -017 are robust randomized phase-three data, with the longest published follow up of patients being on therapy available for a PD-1 inhibitor in lung cancer, across histologies,” Hossein Borghaei, chief of thoracic oncology at Fox Chase Cancer Center, said. “Data presented at ASCO underscore the potential of Opdivo to improve long-term outcomes for patients with this particularly challenging disease.”
The researchers are encouraged with these results.
“Our fundamental goal for immuno-oncology research is to redefine the expectation of long-term, quality survival for all patients with lung cancer,” Nick Botwood, development lead for Lung and Head & Neck, Bristol-Myers Squibb, said. “We will seek to continue to leverage our deep scientific expertise and our unwavering commitment to patients to deliver transformative cancer care. Today, these data from CheckMate -057 and -017 expand our understanding of the potential for Opdivo to provide a meaningful, durable survival benefit to patients with previously treated metastatic NSCLC.”